Crossmark

Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1007/s10147-022-02174-0

Published Online: 2022-05-28

Published Print: 2022-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Shimada, Shu

Tanaka, Shinji https://orcid.org/0000-0002-7718-3453
Funding

Funding for this research was provided by:

The Ministry of Education, Culture, Sports, Science and Technology of Japan (19H01055)

The Ministry of Education, Culture, Sports, Science and Technology of Japan (20K21627)

Japan Agency for Medical Research and Development (JP19cm0106540)

Japan Agency for Medical Research and Development (JP21fk0210090)

Japan Agency for Medical Research and Development (JP20fk0210060)
License Information

Text and Data Mining valid from 2022-05-28

Version of Record valid from 2022-05-28
More Information

Article History

Received: 31 January 2022

Accepted: 17 April 2022

First Online: 28 May 2022

Declarations

:

: The authors declare no potential conflicts of interest.

Document is current

Any future updates will be listed below